The war against Alzheimer, the mitochondrion strikes back! 2022

Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
Universidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, Escuela de Medicina, 17-12-841, Quito, Ecuador; Universidad San Francisco de Quito USFQ, Instituto de Investigaciones en Biomedicina, 17-12-841, Quito, Ecuador; School for Mental Health and Neuroscience (MHeNs), Maastricht University, Maastricht, the Netherlands; Mito-Act Research Consortium, Quito, Ecuador; Instituto de Neurociencias, Universidad San Francisco de Quito USFQ, Quito, Ecuador.

Alzheimer's disease (AD) is a leading neurodegenerative pathology associated with aging worldwide. It is estimated that AD prevalence will increase from 5.8 million people today to 13.8 million by 2050 in the United States alone. AD effects in the brain are well known; however, there is still a lack of knowledge about the cellular mechanisms behind the origin of AD. It is known that AD induces cellular stress affecting the energy metabolism in brain cells. During the pathophysiological advancement of AD, damaged mitochondria enter a vicious cycle, producing reactive oxygen species (ROS), harming mitochondrial DNA and proteins, leading to more ROS and cellular death. Additionally, mitochondria are interconnected with the plaques formed by amyloid-β in AD and have underlying roles in the progression of the disease and severity. For years, the biomedical field struggled to develop new therapeutic options for AD without a significant advancement. However, mitochondria are striking back existing outside cells in a new mechanism of intercellular communication. Extracellular mitochondria are exchanged from healthy to damaged cells to rescue those with a perturbed metabolism in a process that could be applied as a new therapeutic option to repair those brain cells affected by AD. In this review we highlight key aspects of mitochondria's role in CNS' physiology and neurodegenerative disorders, focusing on AD. We also suggest how mitochondria strikes back as a therapeutic target and as a potential agent to be transplanted to repair neurons affected by AD.

UI MeSH Term Description Entries
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D004272 DNA, Mitochondrial Double-stranded DNA of MITOCHONDRIA. In eukaryotes, the mitochondrial GENOME is circular and codes for ribosomal RNAs, transfer RNAs, and about 10 proteins. Mitochondrial DNA,mtDNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D016229 Amyloid beta-Peptides Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue. Alzheimer beta-Protein,Amyloid Protein A4,Amyloid beta-Peptide,Amyloid beta-Protein,beta Amyloid,beta-Amyloid Protein,Alzheimer's ABP,Alzheimer's Amyloid Fibril Protein,Amyloid AD-AP,Amyloid Fibril Protein, Alzheimer's,Amyloid beta-Proteins,ABP, Alzheimer's,AD-AP, Amyloid,Alzheimer ABP,Alzheimer beta Protein,Alzheimers ABP,Amyloid AD AP,Amyloid beta Peptide,Amyloid beta Peptides,Amyloid beta Protein,Amyloid beta Proteins,Amyloid, beta,Protein A4, Amyloid,Protein, beta-Amyloid,beta Amyloid Protein,beta-Peptide, Amyloid,beta-Peptides, Amyloid,beta-Protein, Alzheimer,beta-Protein, Amyloid,beta-Proteins, Amyloid
D017382 Reactive Oxygen Species Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of SIGNAL TRANSDUCTION and GENE EXPRESSION, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS. Active Oxygen Species,Oxygen Radical,Oxygen Radicals,Pro-Oxidant,Reactive Oxygen Intermediates,Active Oxygen,Oxygen Species, Reactive,Pro-Oxidants,Oxygen, Active,Pro Oxidant,Pro Oxidants,Radical, Oxygen

Related Publications

Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
July 1997, Nature genetics,
Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
February 2019, Journal of Korean medical science,
Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
December 1993, Current opinion in immunology,
Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
September 2003, The British journal of sociology,
Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
January 1997, Nature biotechnology,
Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
November 2003, Texas medicine,
Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
January 2012, Eplasty,
Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
August 2023, Korean circulation journal,
Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
December 2016, Blood,
Kevin Zambrano, and Diego Barba, and Karina Castillo, and Paola Robayo, and Dariana Argueta-Zamora, and Serena Sanon, and Eduardo Arizaga, and Andres Caicedo, and Antonio W D Gavilanes
January 1999, Nursing times,
Copied contents to your clipboard!